115 related articles for article (PubMed ID: 9112432)
1. P53 protein expression in human multidrug-resistant CEM lymphoblasts.
Rafki N; Liautaud-Roger F; Devy L; Trentesaux C; Dufer J
Leuk Res; 1997 Feb; 21(2):147-52. PubMed ID: 9112432
[TBL] [Abstract][Full Text] [Related]
2. Differences in mutant p53 protein stability and functional activity in teniposide-sensitive and -resistant human leukemic CEM cells.
Morgan SE; Kim R; Wang PC; Bhat UG; Kusumoto H; Lu T; Beck WT
Oncogene; 2000 Oct; 19(43):5010-9. PubMed ID: 11042688
[TBL] [Abstract][Full Text] [Related]
3. Activity of drugs from traditional Chinese medicine toward sensitive and MDR1- or MRP1-overexpressing multidrug-resistant human CCRF-CEM leukemia cells.
Efferth T; Davey M; Olbrich A; Rücker G; Gebhart E; Davey R
Blood Cells Mol Dis; 2002; 28(2):160-8. PubMed ID: 12064912
[TBL] [Abstract][Full Text] [Related]
4. Cytosine arabinoside (ara-C) resistance confers cross-resistance or collateral sensitivity to other classes of anti-leukemic drugs.
Martin-Aragon S; Mukherjee SK; Taylor BJ; Ivy SP; Fu CH; Ardi VC; Avramis VI
Anticancer Res; 2000; 20(1A):139-50. PubMed ID: 10769646
[TBL] [Abstract][Full Text] [Related]
5. Anticancer drug-mediated induction of multidrug resistance-associated genes and protein kinase C isozymes in the T-lymphoblastoid cell line CCRF-CEM and in blasts from patients with acute lymphoblastic leukemias.
Beck JF; Brügger D; Brischwein K; Liu C; Bader P; Niethammer D; Gekeler V
Jpn J Cancer Res; 2001 Aug; 92(8):896-903. PubMed ID: 11509123
[TBL] [Abstract][Full Text] [Related]
6. A serine 37 mutation associated with two missense mutations at highly conserved regions of p53 affect pro-apoptotic genes expression in a T-lymphoblastoid drug resistant cell line.
Cinti C; Claudio PP; Luca AD; Cuccurese M; Howard CM; D'Esposito M; Paggi MG; Sala DL; Azzoni L; Halazonetis TD; Giordano A; Maraldi NM
Oncogene; 2000 Oct; 19(44):5098-105. PubMed ID: 11042698
[TBL] [Abstract][Full Text] [Related]
7. Modulation of multidrug resistance in human leukemia cells with mdr1-targeted antisense oligonucleotides using variable treatment schedules.
Dassow H; Lassner D; Remke H; Preiss R
Int J Clin Pharmacol Ther; 2000 Apr; 38(4):209-16. PubMed ID: 10783831
[TBL] [Abstract][Full Text] [Related]
8. mdm2 gene mediates the expression of mdr1 gene and P-glycoprotein in a human glioblastoma cell line.
Kondo S; Kondo Y; Hara H; Kaakaji R; Peterson JW; Morimura T; Takeuchi J; Barnett GH
Br J Cancer; 1996 Oct; 74(8):1263-8. PubMed ID: 8883415
[TBL] [Abstract][Full Text] [Related]
9. Alterations of vinblastine influx in multidrug-resistant lymphoblastic leukaemic CEM cells.
Colin M; Madoulet C; Warren L; Jardillier JC
Anticancer Res; 1996; 16(1):407-12. PubMed ID: 8615645
[TBL] [Abstract][Full Text] [Related]
10. The high levels of p53 present in adenovirus early region 1-transformed human cells do not cause up-regulation of MDM2 expression.
Grand RJ; Lecane PS; Owen D; Grant ML; Roberts S; Levine AJ; Gallimore PH
Virology; 1995 Jul; 210(2):323-34. PubMed ID: 7618270
[TBL] [Abstract][Full Text] [Related]
11. Selective compartmentalization of different mdm2 proteins within the nucleus.
Maxwell SA
Anticancer Res; 1994; 14(6B):2541-7. PubMed ID: 7872679
[TBL] [Abstract][Full Text] [Related]
12. Impact of BCRP/MXR, MRP1 and MDR1/P-Glycoprotein on thermoresistant variants of atypical and classical multidrug resistant cancer cells.
Stein U; Lage H; Jordan A; Walther W; Bates SE; Litman T; Hohenberger P; Dietel M
Int J Cancer; 2002 Feb; 97(6):751-60. PubMed ID: 11857350
[TBL] [Abstract][Full Text] [Related]
13. Nuclear DNA content and chromatin texture in multidrug-resistant human leukemic cell lines.
Dufer J; Millot-Broglio C; Oum'Hamed Z; Liautaud-Roger F; Joly P; Desplaces A; Jardillier JC
Int J Cancer; 1995 Jan; 60(1):108-14. PubMed ID: 7814142
[TBL] [Abstract][Full Text] [Related]
14. Drug-resistant breast cancer cells frequently retain expression of a functional wild-type p53 protein.
Gudas JM; Nguyen H; Li T; Sadzewicz L; Robey R; Wosikowski K; Cowan KH
Carcinogenesis; 1996 Jul; 17(7):1417-27. PubMed ID: 8706243
[TBL] [Abstract][Full Text] [Related]
15. Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines.
Keshelava N; Zuo JJ; Chen P; Waidyaratne SN; Luna MC; Gomer CJ; Triche TJ; Reynolds CP
Cancer Res; 2001 Aug; 61(16):6185-93. PubMed ID: 11507071
[TBL] [Abstract][Full Text] [Related]
16. Characterization and modulation of drug resistance of human paediatric rhabdomyosarcoma cell lines.
Cocker HA; Pinkerton CR; Kelland LR
Br J Cancer; 2000 Aug; 83(3):338-45. PubMed ID: 10917549
[TBL] [Abstract][Full Text] [Related]
17. Energy-dependent reduced drug binding as a mechanism of Vinca alkaloid resistance in human leukemic lymphoblasts.
Beck WT; Cirtain MC; Lefko JL
Mol Pharmacol; 1983 Nov; 24(3):485-92. PubMed ID: 6579344
[TBL] [Abstract][Full Text] [Related]
18. Rapid up-regulation of mdr1 expression by anthracyclines in a classical multidrug-resistant cell line.
Hu XF; Slater A; Wall DM; Kantharidis P; Parkin JD; Cowman A; Zalcberg JR
Br J Cancer; 1995 May; 71(5):931-6. PubMed ID: 7734315
[TBL] [Abstract][Full Text] [Related]
19. Functional and gene expression analysis of the p53 signaling pathway in clear cell sarcoma of the kidney and congenital mesoblastic nephroma.
Brownlee NA; Hazen-Martin DJ; Garvin AJ; Re GG
Pediatr Dev Pathol; 2002; 5(3):257-68. PubMed ID: 12007018
[TBL] [Abstract][Full Text] [Related]
20. Human lymphoblastoid cell lines expressing mutant p53 exhibit decreased sensitivity to cisplatin-induced cytotoxicity.
Piovesan B; Pennell N; Berinstein NL
Oncogene; 1998 Nov; 17(18):2339-50. PubMed ID: 9811465
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
